← FDA DRUG APPROVALS

FDA ANDA · ANDA210181

MYCOPHENOLATE MOFETIL

Sponsor: CONCORD BIOTECH LTD

APPLICATION
ANDA210181
TYPE
ANDA
ORIGINAL APPROVAL
2019-01-08
LATEST ACTION
2026-07-29
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

MYCOPHENOLATE MOFETILPrescription
MYCOPHENOLATE MOFETIL 250MG · CAPSULE · ORAL

Approval history

2026-07-29REMS · Supplement 25AP
2024-08-13REMS · Supplement 20AP
2024-07-08Labeling · Supplement 18 · standardAP
2022-11-16Labeling · Supplement 15 · standardAP
2021-08-11REMS · Supplement 9AP
2021-04-21REMS · Supplement 8AP
2021-01-15REMS · Supplement 6AP
2019-11-25Labeling · Supplement 1 · standardAP
2019-01-08UNKNOWN · Original · standardREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →